Proviral Sequencing Driven Development of Enhanced IPDAv2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials

该项目的目标是开发和商业化基于序列的HIV病毒库检测，用于临床HIV治愈干预。在临床研究和前瞻性临床试验中，该检测方法应被设计成一种分析工具，用于监测具有复制能力的HIV病毒库的大小。该计划的另一个目标是开发非组织培养为基础的二级分析，并区分活性转录和潜伏全长原病毒。该合同旨在开发和验证IPDA的第2版，用于主要的HIV-1 M组亚型和重组。

The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-based and discriminate between actively transcribed and latent full-length proviruses. This contract is to develop and validate version 2 of the IPDA for use across major HIV-1 Group M subtypes and recombinants.